MedTrace Logo

Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China

NCT03514030 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2018-05-02

No results posted yet for this study

Summary

In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other persons found highly specific AQP4（aquaporin 4）antibodies in NMO patients'sera, and further differentiated between NMO and MS, confirming that NMO is an independent disease.At present, NMO has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.In 2015, the international NMO diagnostic team developed the diagnostic criteria based on highly specific AQP4 antibodie.Up to now, in China, there is no data on the number of NMOSD patients, the rate of misdiagnosis, the treatment methods, and the prognosis.This study is committed to build China's NMOSD big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.

Conditions

  • NMO Spectrum Disorder;Registry Study

Interventions

DIAGNOSTIC_TEST

serum AQP4-antibody testing method

there are different methods of testing serum AQP4-antibody

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-04-30
Completion
2021-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03514030 on ClinicalTrials.gov